Author: Michelow, Ian C.; Lear, Calli; Scully, Corinne; Prugar, Laura I.; Longley, Clifford B.; Yantosca, L. Michael; Ji, Xin; Karpel, Marshall; Brudner, Matthew; Takahashi, Kazue; Spear, Gregory T.; Ezekowitz, R. Alan B.; Schmidt, Emmett V.; Olinger, Gene G.
Title: High-Dose Mannose-Binding Lectin Therapy for Ebola Virus Infection Document date: 2011_1_15
ID: jvs25q21_2
Snippet: Circulating mannose-binding lectin (MBL) is a first-line host defense against a wide range of viral and other pathogens. MBL is a C-type lectin that recognizes hexose sugars including mannose, glucose, fucose, and N-acetylglucosamine on the surface of many pathogens. It does not recognize the terminal carbohydrates galactose and sialic acid on normal host cells. Therefore, MBL preferentially recognizes glycosylated viruses including influenza vir.....
Document: Circulating mannose-binding lectin (MBL) is a first-line host defense against a wide range of viral and other pathogens. MBL is a C-type lectin that recognizes hexose sugars including mannose, glucose, fucose, and N-acetylglucosamine on the surface of many pathogens. It does not recognize the terminal carbohydrates galactose and sialic acid on normal host cells. Therefore, MBL preferentially recognizes glycosylated viruses including influenza virus, human immunodeficiency virus, severe acute respiratory syndrome coronovirus (SARS-CoV), Ebola virus, and Marburg virus. It also recognizes many glycosylated grampositive and gram-negative bacteria [1, 2] . As a result of common genetic variants, MBL serum levels in humans range from 0 to 10,000 ng/mL. Thirty percent of the human population has levels ,500 ng/mL, which are associated with increased susceptibility to infections in children and immunocompromised individuals [3] .
Search related documents:
Co phrase search for related documents- host defense and human immunodeficiency virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- host defense and human immunodeficiency virus influenza virus: 1, 2, 3, 4
- host defense and human population: 1, 2, 3, 4
- host defense and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48
- host defense and MBL serum: 1
- host defense and sialic acid: 1, 2, 3
- host defense and viral pathogen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- host defense and wide range: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- human immunodeficiency and increase susceptibility: 1, 2, 3
- human immunodeficiency and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- human immunodeficiency and mannose bind: 1, 2
- human immunodeficiency and Marburg virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- human immunodeficiency and Marburg virus Ebola virus: 1, 2, 3, 4, 5, 6
- human immunodeficiency and pathogen surface: 1
- human immunodeficiency and sialic acid: 1, 2
- human immunodeficiency and terminal carbohydrate: 1
- human immunodeficiency and Thirty percent: 1
- human immunodeficiency and viral pathogen: 1, 2, 3, 4
- human immunodeficiency and wide range: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
Co phrase search for related documents, hyperlinks ordered by date